Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scandinavian Journal of Immunology|July 18, 2002
Current state of pneumococcal vaccinesT Wuorimaa, H Käyhty
Vaccine|March 3, 2001
Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adultsT Wuorimaa, H Käyhty, O Leroy, et al.
Clinical and Diagnostic Laboratory Immunology|July 17, 1998
Assignment of immunoglobulin G1 and G2 concentrations to pneumococcal capsular polysaccharides 3, 6B, 14, 19F, and 23F in pneumococcal reference serum 89-SFA Soininen, I Seppälä, T Wuorimaa, et al.
Vaccine|October 24, 2001
Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlersR M Olander, T Wuorimaa, H Käyhty, et al.
Scandinavian Journal of Immunology|April 4, 2001
Activation of cell-mediated immunity following immunization with pneumococcal conjugate or polysaccharide vaccineT Wuorimaa, H Käyhty, J Eskola, et al.
The Pediatric Infectious Disease Journal|April 17, 2001
Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlersT Wuorimaa, R Dagan, J Eskola, et al.
The Journal of Infectious Diseases|October 13, 2001
Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvantT Wuorimaa, R Dagan, M Väkeväinen, et al.
Bone Marrow Transplantation|September 22, 1999
IgG subclasses and avidity of antibodies to polysaccharide antigens in allogeneic BMT recipients after vaccination with pneumococcal polysaccharide and Haemophilus influenzae type b conjugate vaccinesT Parkkali, H Käyhty, M Anttila, et al.
Annals of Neurology|October 1, 1996
Complement activation in the central nervous system following blood-brain barrier damage in manP J Lindsberg, J Ohman, T Lehto, et al.
Pageof 1